Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | RESILIENT: liposomal irinotecan in relapsed SCLC

David R. Spigel, MD, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, discusses the ongoing phase III RESILIENT study (NCT03088813) which aims to evaluate the efficacy of liposomal irinotecan against standard topotecan therapy in relapsed small cell lung cancer (SCLC) patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).